Fangda Partners
Fangda Partners offers an extensive life sciences and healthcare focussed team representing an array of medical technology companies and investors, both PRC and multinational. The team is particularly recommended for its expertise in financing and fundraisings. Practice head Josh Shin is expert on regulatory-related issues including R&D, clinical trials, HGRAC regulation and patient centric transformation. Kate Yin is recommended for handling investigations work in the healthcare space, covering anti-bribery, accounting fraud, securities law, conflict of interest, trade secrets and data security. IP expert Fang Qi, antitrust investigations specialist Michael Han and the M&A and foreign investment focussed Diana Li are also central to the team. Henry He, who joined the firm from C-Stone Pharmaceuticals in January 2023, is a further key name.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The staff has a keen awareness and rich experience in regulatory changes and regulatory practices in the pharmaceutical industry, which is trustworthy.’
‘We trust their professional interpretation and advice.'
‘Fangda's life science and health care lawyer team is very professional and can provide efficient services to clients, including different types of transactions in this field, such as CMO under the background of MAH reform of drug management law and other project legal services.'
‘Josh Shin is an outstanding partner.'
‘Can provide one-stop legal services for pharmaceutical companies and life science and technology companies.’
‘Diana Li has deep insights into the pharmaceutical industry and knows how to provide professional legal services to pharmaceutical clients.’
‘With significant and long-term industry experience in the field of life sciences and healthcare, as well as outstanding achievements in domestic and overseas financing, the team is stable and provides continuous legal support to clients.’
‘One of the very best PRC law firms that can provide full services to its clients.’
Key clients
- Eight-Roads Capital
- Hengrui Pharmaceuticals
- Duality BioScience
- Sandoz
- Carl Zeiss
- Organon
- Haleon
- Beijing Kexing
- Novartis
- Bayer Healthcare
- AstraZeneca
- Roche China
- Gilead Sciences
- Abbott China
- WuXi AppTech
- Watson Pharmaceuticals
- Mindray Medical
- APBI Holdings
- Danaher Corporate
- BeiGene
- TPG Growth
- Sino Medcare
- Roper Technology
- Assembly BioScience
- Edding Pharm
- Everbright Healthcare Fund
- C-Stone Pharmaceutical
- Hanhui Pharma
- Shanghai Kehua Bioengineering
- Astellas
- Brooks Automation
- EdiGene Beijing Biotechnology
- LifeTech Scientific Corporation
- Wuxi JW Therapeutics
- CBC Group
- PAG
- Primavera Capital
- CDBI Capital
- CICC Healthcare Fund
- CVC Capital
- Hillhouse Capital
- Highlight Capital
- Haeir Healthcare
- Johnson & Johnson
- Straumann
- Anheart Therapeutics
- Smith & Nephew
- MitrAssist
- Visen Pharmaceuticals
- Laekna Therapeutics
- Smith & Nephew
- Vyaire Medical
- MSD
- Vazyme Biotechnology
- Zai Lab
- CMS (China Medical System)
- CDH Fund
- Novotech
- MicroPort Group
- Cenova Capital
- Bristol-Myers Squibb
- Medi-Link
- I-Mab BioPharma
- Brii BioScience
- Overland Pharmaceuticals
- Oncusp Therapeutics
- Galixir Technology
- Virogin Biotech
- Thermo Fisher
- Ortho Diagnostics
- Eli Lilly
- Takeda
- Kintor Pharmaceutical
- MediTrust Health
- AZ-CICC Healthcare Fund
- magAssist Technology
- Perkin Elmer
- Beijing Naton Technology
Work highlights
- Represented InnoCare Pharma Limited as the company counsel in its STAR Market listing in Shanghai to raise RMB 2.9 billion, after its IPO on HKEX.
- Advised MediTrust Health on its Series C+ financing led by HSBC and its entering into strategic agreement with HSBC.
- Acted as PRC counsel of Abu Dhabi Investment Authority (“ADIA”) as the lead investor in its equity investment in CBPO Holdings Limited (“CBPO”, the offshore holding company of Taibang Biologics), with the total purchase price of US$ 300,000,000.
Lawyers
Leading individuals
Practice head
The lawyer(s) leading their teams.
Josh Shin